-
Zuellig Pharma Partners with Regeneron for Libtayo Launch in South Korea and Taiwan
•
Singapore-headquartered Zuellig Pharma, a leading healthcare solutions provider, has entered into an agreement with US pharmaceutical giant Regeneron Pharmaceuticals Inc. to oversee the market launch and commercialization of Libtayo (cemiplimab), Regeneron’s proprietary programmed death-1 (PD-1) inhibitor, in South Korea and Taiwan. Financial details of the agreement were not disclosed. Libtayo…
-
Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets
•
Zuellig Pharma, a Singapore-based healthcare solutions provider, has announced the expansion of its commercialization agreement with Sweden-based Karo Healthcare. According to the new terms, Zuellig will serve as the exclusive commercialization partner for Karo’s over-the-counter (OTC) anti-fungal treatment Lamisil (terbinafine hydrochloride) across key Asian markets, including Hong Kong, Malaysia, Philippines,…
-
Zuellig Pharma Partners with Substipharm Biologics for Japanese Encephalitis Vaccine Distribution
•
Singapore-based healthcare company Zuellig Pharma has announced the establishment of a commercialization partnership with France-based Substipharm Biologics. The partnership centers around Substipharm’s Japanese encephalitis (JE) vaccine, Imojev. Zuellig Pharma will offer marketing and distribution support, aiming to make the vaccine accessible to patients across nine Asian markets, including Brunei, Cambodia,…
